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PA and 4) Global Obesity Prevention Center (GOPC), Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USAAbstractAccurate diagnosis of Clostridium difﬁcile infection (CDI) is essential to effectively managing patients and preventing transmission. Despite the
availability of several diagnostic tests, the optimal strategy is debatable and their economic values are unknown. We modiﬁed our previously
existing C. difﬁcile simulation model to determine the economic value of different CDI diagnostic approaches from the hospital perspective.
We evaluated four diagnostic methods for a patient suspected of having CDI: 1) toxin A/B enzyme immunoassay, 2) glutamate dehydrogenase
(GDH) antigen/toxin AB combined in one test, 3) nucleic acid ampliﬁcation test (NAAT), and 4) GDH antigen/toxin AB combination test with
NAAT conﬁrmation of indeterminate results. Sensitivity analysis varied the proportion of those tested with clinically signiﬁcant diarrhoea, the
probability of CDI, NAAT cost and CDI treatment delay resulting from a false-negative test, length of stay and diagnostic sensitivity and
speciﬁcity. The GDH/toxin AB plus NAAT approach leads to the timeliest treatment with the fewest unnecessary treatments given,
resulted in the best bed management and generated the lowest cost. The NAAT-alone approach also leads to timely treatment. The
GDH/toxin AB diagnostic (without NAAT conﬁrmation) approach resulted in a large number of delayed treatments, but results in the
fewest secondary colonisations. Results were robust to the sensitivity analysis. Choosing the right diagnostic approach is a matter of cost
and test accuracy. GDH/toxin AB plus NAAT diagnosis led to the timeliest treatment and was the least costly.
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E-mail: brucelee@jhu.eduIntroductionClostridium difﬁcile is the leading cause of infectious nosocomial
diarrhoea and causes considerable morbidity and mortality,
especially in elderly and frail hospital patients [1–3]. These in-
fections result in substantial healthcare costs [4]. AccurateClinical Microbiology and Infection © 2014 European Society of Cdiagnosis is key to effectively managing patients with C. difﬁcile
and implementing infection control measures to interrupt
transmission [2,5–7]. No diagnostic test for C. difﬁcile infection
(CDI) is 100% sensitive or speciﬁc, and thus can result in false-
positive and false-negative results, leading to unnecessary and
delayed treatments, respectively. Delayed treatments may
result in increased C. difﬁcile transmission and increased risk of
adverse outcomes [5]. Evidence has shown that rapid diagnosis
of C. difﬁcile has a positive impact on patient care [6].
There are several diagnostic tests for C. difﬁcile, each with its
own strengths and weaknesses (e.g. poor sensitivity or speci-
ﬁcity, long turnaround time, high cost). Tests to identify
C. difﬁcile toxins by immunoassay tend to be easier to perform,
are less costly and have a shorter turnaround time than otherClin Microbiol Infect 2015; 21: 77.e1–77.e9
linical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved
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Newer molecular-based tests to detect C. difﬁcile toxin genes
(i.e. tcdA and tcdB genes) have greater sensitivity but may have
decreased speciﬁcity for clinical disease and can be costly.
Implementation of these tests and diagnostic algorithms (e.g.
two-step testing) vary widely in hospital laboratories across the
country. Effectively and efﬁciently diagnosing CDI remains a
challenge for clinicians and clinical microbiologists [2]. Addi-
tionally, the optimal strategy to provide timely, cost-effective
and accurate results remains controversial [2,8].
Numerous studies have evaluated the performance of
C. difﬁcile diagnostic tests and algorithms (singly and head to head),
but none have evaluated their economic value. Determining the
economic value of the various diagnostic approaches forC. difﬁcile
can help policy makers, hospital administrators and laboratory
directors and clinicians decide which tests should be used in
clinical practice (based on local circumstances).MethodsUsing TreeAge Pro 2013 (Williamstown, MA), we modiﬁed our
previously published C. difﬁcile models [4,9,10] to determine the
economic value of different CDI diagnostic approaches from
the hospital perspective. Fig. 1 provides a schematic of the
diagnostic approaches we examined, and our model input pa-
rameters are summarized in Appendix Table 1.
Patients who had C. difﬁcile diagnostic tests ordered (had
sample submitted for testing) entered the model. In clinical
practice, some of these patients are tested for C. difﬁcile when
they do not have clinically signiﬁcant diarrhoea or other
symptoms consistent with a clinical diagnosis of CDI, contrary
to clinical guidelines [2]. To account for this practice, we
assigned a probability of presenting with symptoms that are
consistent with guidelines for appropriate C. difﬁcile testing. Of
those patients presenting with symptoms, a proportion of them
were treated empirically, representing patients with severe
disease and a subset of those with nonsevere disease who may
be treated pending a test result.
All patients entering the model were placed under pre-
sumptive contact isolation and could be diagnosed by one of
any four approaches:
1) Toxin AB enzyme immunoassay (EIA): measures C. difﬁcile
toxin A and B; test results are either positive or negative.
A negative test result for a patient with clinically
signiﬁcant diarrhoea prompts a request for one repeat
test with its associated additional turnaround time.
2) Glutamate dehydrogenase (GDH) antigen/toxin AB
combination test: tests for GDH and C. difﬁcile toxin A andClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and InfectB in one test (e.g. TECHLAB C. Diff Quik Chek Complete).
If both portions are positive, the test result is considered
true positive; if both the GDH and toxin AB portions are
negative, the test is considered true negative. Indeterminate
results (GDH positive, toxin AB negative; and GDH
negative, toxin AB positive) required a new sample from a
patient with clinically signiﬁcant diarrhoea, adding another
day to the turnaround time (no additional action was taken
for a patient without clinically signiﬁcant diarrhoea). In our
model, an indeterminate result on repeat testing is
considered to be positive based on clinical suspicion.
3) Nucleic acid ampliﬁcation test (NAAT): detects toxin genes
(tcdA and tcdB); test results are either positive or negative.
4) GDH antigen/toxin AB combination with NAAT
conﬁrmation of indeterminate results: stool samples were
ﬁrst tested with the GDH/toxin AB combination test
(described earlier). Indeterminate samples were then
tested with NAAT, and were attributed the costs of both
the combination and NAAT tests. No additional stool
samples were required.
A patient was deemed to be C. difﬁcile positive based on the
sensitivity and speciﬁcity of the diagnostic test and the proba-
bility that a patient actually had a C. difﬁcile infection. The
sensitivity and speciﬁcity estimates utilized for each of the
diagnostic approaches were those that compared the tests to
toxigenic culture. Patients who started empiric therapy were
discontinued upon a negative test result, unless they had severe
disease (probability in Appendix Table 1). Unless the patient
continued their empiric therapy, contact isolation precautions
had a probability of being discontinued upon a negative test
result. They remained in place until hospital discharge for those
with a positive test result. Isolation continued for those with an
indeterminate result until a diagnosis was made, either by an
additional test or clinical suspicion. CDI patients could freely
transmit to other patients based on C. difﬁcile’s reproductive
rate (R), which is the average number of secondary colonisa-
tions generated by one CDI patient, regardless of the mode of
transmission. Staff compliance with contact isolation pre-
cautions attenuated this transmission, when in place.
Patients accurately identiﬁed as true positives received
appropriate and timely treatment; patients identiﬁed as false
negatives were assumed to have delayed treatment (unless they
started and continued empiric therapy); false-positive patients
were considered to have received unnecessary treatment.
Delayed treatment extended a patient’s length of stay, as did
any additional turnaround time for repeat tests. Additionally,
patients whose contact precautions were removed after a false-
negative test result were put back on contact precautions when




FIG. 1. Model ﬂow for the various CDI diagnostic testing strategies. CDI, Clostridium difﬁcile infection; GDH, glutamate dehydrogenase; NAAT, nucleic
acid ampliﬁcation test.
CMI Bartsch et al. Economics of C. difﬁcile diagnostics 77.e3The model sent 1000 possible adult CDI patients (aged 18
years) through the model 1000 times (1 million total unique
outcomes). Outcome measures included cost; number of
timely, delayed and unnecessary treatments; and unnecessary
additional bed days (length of stay) for those with delayed
treatment.Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology andThe hospital perspective estimated costs per bed day of a
patient’s length of stay. In this way, we estimate opportunity
costs for lost bed days due to additional length of stay attrib-
utable to CDI following a method described by Graves [11]. As
the cost per bed day was derived from the Healthcare Utili-
zation Project (HCUP) [12], it includes service chargesInfectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 77.e1–77.e9
77.e4 Clinical Microbiology and Infection, Volume 21 Number 1, January 2015 CMI(converted to costs) associated with a patient’s hospital stay,
including room and board (e.g. if the patient had an additional
charge for being in a private room, that would be included).
This perspective also included the costs associated with the
diagnostic tests and contact precautions. Baseline diagnostic
test costs came from the Centers for Medicare and Medicaid
Services clinical diagnostic laboratory fee schedule [13]. All
costs were age speciﬁc when available and were discounted to
2014 US$ using a 3% discount rate. Patient age was based on
statistics from HCUP for ICD-9 code 008.45 for those with
CDI and all hospital stays for those without CDI.
Sensitivity analysis varied the probability of presenting with
symptoms/having clinically signiﬁcant diarrhoea (60%, 70%, 80%
and 100%) [14–16], the probability of infection (5%, 10%, 15%,
20% and 25%) given symptoms, treatment delays associated
with a false-negative result (1, 3 and 5 days), staff compliance
with contact precautions (60% and 75%), the probability of
contact precautions being removed upon false-negative test
results (25%, 50% and 75%), and cost of the NAAT diagnostic
test (from the current cost to the cost of the other tests).
Additional scenarios evaluated the impact of changing the length
of stay (to 18.6 for CDI patients and 14.2 for non-CDI patients
[17]), having no repeat toxin AB testing for negative results, and
the sensitivity and speciﬁcity of the diagnostic tests. For the
latter, two-way sensitivity analyses were performed, as well as
additional scenarios using test characteristics based on clinical
reference standards for the tests where this data was available
(Appendix Table 1). In addition, Monte Carlo probabilisticTABLE 1. Cost [median (95% credible range)] per person when co
those with a delay in treatment when 60% and 80% of patients test
Probability of CDI
Diagnostic approach
Toxin AB GDH/toxin AB
60% of patients tested have clinically signiﬁcant diarrhoea
1-day treatment delay
5% 599 (428 to 797) 562 (394 to 759)
10% 1129 (874 to 1376) 1085 (835 to 1334
15% 1648 (1338 to 1994) 1596 (1289 to 193
20% 2168 (1825 to 2528) 2107 (1767 to 246
25% 2696 (2288 to 3088) 2626 (2234 to 300
5-day treatment delay
5% 629 (446 to 780) 559 (396 to 749)
10% 1178 (942 to 1479) 1075 (849 to 1346
15% 1738 (1438 to 2068) 1593 (1316 to 190
20% 2293 (1929 to 2682) 2113 (1777 to 248
25% 2862 (2464 to 3290) 2638 (2276 to 302
80% of patients tested have clinically signiﬁcant diarrhoea
1-day treatment delay
5% 768 (559 to 989) 721 (521 to 944)
10% 1481 (1175 to 1760) 1423 (1122 to 169
15% 2186 (1829 to 2533) 2118 (1763 to 245
20% 2887 (2481 to 3293) 2807 (2412 to 320
25% 3580 (3139 to 4035) 3492 (3045 to 393
5-day treatment delay
5% 822 (605 to 1059) 732 (536 to 951)
10% 1573 (1260 to 1900) 1432 (1149 to 175
15% 2292 (1915 to 2674) 2104 (1767 to 247
20% 3063 (2652 to 3504) 2819 (2444 to 321
25% 3799 (3340 to 4268) 3513 (3084 to 393
CDI, Clostridium difﬁcile infection; GDH, glutamate dehydrogenase; NAAT, nucleic acid ampl
Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectsensitivity analyses simultaneously varied each parameter
throughout its range listed in the Appendix.ResultsTable 1 shows the median cost (and 95% credible range) per
person with a sample submitted for testing (given current diag-
nostic test costs). Although GDH/toxin AB plus NAAT testing
tended to generate the lowest costs, the differences among all four
diagnostic strategies were not signiﬁcant. When testing 1000
possible patients, GDH/toxin AB plus NAAT testing saved
$33,602,$36,983 and$39,626 compared with the toxin AB
and NAAT approaches for a 1-, 3- and 5-day treatment delay,
respectively. Savings increased when increasing the proportion of
thosewith clinically signiﬁcant diarrhoea among those tested. For a
given probability of CDI, the costs were similar across the range of
treatment delays examined (i.e. additional bed day costs due to
treatment delays did not have a big impact on total cost). Even if the
NAAT test cost the same as the other tests, GDH/toxin AB plus
NAAT was still the least costly approach, although not by much
(NAAT approach cost only $4 to $53 more per patient tested).
Fig. 2 shows the number of timely and delayed treatments
and total costs (in millions) per 1000 patients tested for CDI
when only 80% presented with clinically signiﬁcant diarrhoea
and with a 3-day treatment delay for false negatives. For all
probabilities of CDI, diagnosis with GDH/toxin AB plus NAAT
led to the greatest number of timely treatments and fewestntact precautions (compliance 60%) are removed from 50% of
ed have clinically signiﬁcant diarrhoea (i.e. should be tested)
NAAT GDH/toxin AB plus NAAT
584 (419 to 780) 551 (385 to 746)
) 1095 (850 to 1333) 1059 (817 to 1296)
6) 1593 (1300 to 1921) 1557 (1262 to 1889)
3) 2088 (1762 to 2441) 2051 (1731 to 2406)
6) 2600 (2219 to 2975) 2563 (2180 to 2934)
592 (425 to 780) 551 (398 to 735)
) 1103 (890 to 1375) 1059 (839 to 1324)
2) 1623 (1348 to 1926) 1571 (1293 to 1864)
3) 2138 (1803 to 2496) 2078 (1748 to 2434)
3) 2655 (2304 to 3052) 2588 (2242 to 2974)
739 (544 to 959) 705 (511 to 925)
7) 1424 (1128 to 1693) 1388 (1095 to 1657)
6) 2105 (1766 to 2435) 2068 (1726 to 2398)
1) 2774 (2389 to 3156) 2737 (2356 to 3122)
7) 3443 (3013 to 3878) 3403 (2967 to 3832)
762 (563 to 989) 721 (534 to 937)
1) 1459 (1182 to 1773) 1409 (1130 to 1717)
2) 2128 (1788 to 2493) 2065 (1734 to 4430)
6) 2842 (2461 to 3250) 2772 (2399 to 3156)
2) 3531 (3100 to 3960) 3453 (3030 to 3873)
iﬁcation test.




FIG. 2. Number of timely CDI treatments, delayed CDI treatments, unnecessary CDI treatments and total costs per 1000 patients tested by
diagnostic approach for various probabilities of CDI with a 3-day treatment delay when 80% of patients with submitted samples had clinically signiﬁcant
diarrhoea. CDI, Clostridium difﬁcile infection; GDH, glutamate dehydrogenase; NAAT, nucleic acid ampliﬁcation test.
CMI Bartsch et al. Economics of C. difﬁcile diagnostics 77.e5treatment delays and generated the lowest total cost
(Fig. 2a–e). The NAAT approach resulted in similar timely
treatment outcomes. For the CDI probabilities tested, the
NAAT approach resulted in 1 to 6 more treatment delays (per
1000 patients) than the GDH/toxin AB plus NAAT approach.
The number of timely and delayed treatments with the toxinClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology andAB and GDH/toxin AB were comparable, but neither was ideal.
Compared to the GDH/toxin AB approach, the toxin AB
approach led to more treatment delays and generated higher
costs. There were 111 and 116 timely treatments (46 and 44
delayed treatments) for the toxin AB and GDH/toxin AB tests,
respectively, for a 20% probability of CDI (Fig. 2d).Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 77.e1–77.e9
77.e6 Clinical Microbiology and Infection, Volume 21 Number 1, January 2015 CMIDelays in diagnosis and treatment also resulted in the use of
beds that could have otherwise been used for other patients.
The impact on bed management is shown in Table 2. As ex-
pected, increasing the treatment delay (from 1 to 5 days)
resulted in longer hospitals stays (i.e. unnecessary additional
bed days). Bed management also was affected by an increasing
CDI probability and testing higher proportions of those with
signiﬁcant diarrhoea. However, given the same prevalence of
CDI, changing the proportion of those tested with clinically
signiﬁcant diarrhoea had no impact. For example, given a 12%
prevalence of CDI, 20 bed days per 1000 patients were lost
with a 3-day delay using NAAT, regardless of the proportion of
patients tested that should have had a sample submitted (i.e.
60% signiﬁcant diarrhoea with a 20% probability of CDI equals
80% signiﬁcant diarrhoea with a 15% probability of CDI). The
GDH/toxin AB plus NAAT approach resulted in the fewest
number of unnecessary bed days used (1 to 25 bed days per
1000 patients), whereas the toxin AB approach resulted in the
worst bed management outcomes (14 to 214 unnecessary bed
days per 1000 patients).
Fig. 2 also shows the number of patients who received un-
necessary treatment for CDI. This number decreases slightly as
the probability of CDI increases, as fewer persons are mis-
diagnosed. The GDH/toxin AB plus NAAT strategy led to the
fewest number of unnecessary treatments (2 per 1000 patients),
closely followed by GDH/toxin AB testing alone (3 to 4 per 1000
patients). Increasing the probability of clinically signiﬁcant diar-
rhoea among those with submitted samples (i.e. getting closer to
only testing those who should be tested) hardly affected the
number of unnecessary treatments. Increasing from 60% to 80%TABLE 2. Number of unnecessary bed days resulting from
delays in CDI diagnosis and treatment (for false-negative
tests) per 1000 patients tested (range represents values from









5% 14–18 9–11 2–2 1–1
10% 28–37 17–22 3–4 2–2
15% 41–55 25–33 5–7 2–3
20% 55–73 33–44 7–9 3–4
25% 68–91 41–55 8–11 4–5
3-day treatment delay
5% 23–31 9–11 5–6 2–3
10% 46–61 17–23 10–13 4–6
15% 68–92 26–35 15–20 7–9
20% 91–122 35–47 20–26 9–12
25% 115–152 44–58 25–33 11–14
5-day treatment delay
5% 32–43 9–12 8–11 4–5
10% 65–86 19–25 17–22 8–10
15% 96–127 27–37 24–33 11–15
20% 127–171 37–49 33–44 14–20
25% 161–214 46–62 41–55 18–25
CDI, Clostridium difﬁcile infection; GDH, glutamate dehydrogenase; NAAT, nucleic
acid ampliﬁcation test.
Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectof patients tested with clinically signiﬁcant diarrhoea resulted in 3
to 6 more unnecessary treatments with toxin AB, 1 more with
GDH/toxin AB, 1 fewer with NAAT and had no change with
GDH/toxin AB plus NAAT.
Fig. 3 shows the number of secondary colonisations gener-
ated for the various probabilities of CDI when 80% of patients
tested had clinically signiﬁcant diarrhoea. The GDH/toxin AB
approach generated the fewest secondary colonisations,
although not by much, because more patients are kept under
contact precautions while a second test is performed or due to
clinical suspicion (Fig. 3b). This ﬁgure also shows the impact of
staff compliance with contact precautions and removal of
contact precautions and treatment delays (for false-negative
test results) on R. As expected, shorter delays and higher
compliance led to fewer secondary colonisations, although not
by much. Changing the probability of removing contact pre-
cautions during treatment delay affected R; when more patients
have precautions removed, more secondary cases are
generated.
Results were robust to changes in estimated lengths of stay
for patients as well as cost per bed day. Increases in length of
stay led to increases in total costs and number of secondary
colonisations. Increases and decreases in CDI’s bed day cost
likewise increased or decreased total costs. Additionally,
removing the repeat test for an initially negative toxin AB result
among those with clinically signiﬁcant diarrhoea had little
impact on the results. Overall, the total costs were similar, the
number of patients who had treatment discontinued and then
started again increased (maximum change of 4 patients) and as
expected, the number of unnecessary bed days increased.
Results also were robust to changes in diagnostic test
sensitivity and speciﬁcity. GDH/toxin AB plus NAAT remained
the least costly approach (both the GDH and toxin AB portions
could have sensitivity and speciﬁcity values 85%). If all other
tests had a 10% reduction in sensitivity and speciﬁcity, NAAT
was the least costly approach with sensitivity values 95.6%
when 80% of those tested had signiﬁcant diarrhoea (20% CDI
probability, 3-day treatment delay) (Appendix Fig. 1a). How-
ever, GDH/toxin AB plus NAAT remained the best approach
given our baseline NAAT sensitivity and speciﬁcity, even when
its own sensitivity and speciﬁcity was reduced by 10%. If all
other tests but NAAT had a 10% reduction in their sensitivity
and speciﬁcity, NAAT was the least costly strategy when
costing less than $32 (Appendix Fig. 1b).
Additional scenarios assumed that clinical guidelines are
followed and only those patients presenting with CDI-like
symptoms have samples submitted for testing (100% clinically
signiﬁcant diarrhoea). In these scenarios, we evaluated the
strategies using sensitivity and speciﬁcity values based on pa-
tients with clinical symptoms (Appendix Table 1). Again, theious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 77.e1–77.e9
(a) (b)
(c) (d)
FIG. 3. Impact of staff compliance with contact precautions, and removal of contact precautions and treatment delay for false-negative test results on
the number of secondary colonisations (R) generated per 1000 patients tested by diagnostic approach when 80% of those tested had clinically sig-
niﬁcant diarrhoea. Lines represent the ends of the range in the number of cases given the best and worst case scenarios tested. CDI, Clostridium difﬁcile
infection; GDH, glutamate dehydrogenase; NAAT, nucleic acid ampliﬁcation test.
CMI Bartsch et al. Economics of C. difﬁcile diagnostics 77.e7GDH/toxin AB plus NAAT approach resulted in the lowest
total cost and best treatment outcomes. However, given the
lower speciﬁcities of the tests, results showed a greater number
of unnecessary treatments, with GDH/toxin AB generating the
fewest (3 to 4 per 1000 patients tested). The NAAT approach
resulted in 111 to 140 unnecessary treatments per 1000 pa-
tients tested, whereas the GDH/toxin AB plus NAAT resulted
in 7 to 8 unnecessary treatments per 1000 patients tested.DiscussionOverall, diagnosis with GDH/toxin AB plus NAAT led to the
timeliest treatment, the fewest unnecessary treatments and was
the least costly. The NAAT approach was comparable to GDH/
toxin AB plus NAAT in terms of timely treatment outcomes.
The GDH/toxin AB plus NAAT approach also had the best bedClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology andmanagement, with the fewest number of unnecessary additional
bed days due to delays in diagnosis and treatment. Therefore,
our results suggest that GDH/toxin AB plus NAAT is the most
cost-effective strategy to diagnose C. difﬁcile under most con-
ditions. Although results were robust to changes in sensitivity
and speciﬁcity, caution should be taken, as the differences in
sensitivities between the GDH/toxin AB plus NAAT conﬁr-
mation vs. NAAT alone are very small and may depend on the
assay used.
Choosing the right diagnostic tool is not only a matter of
cost, but also of test accuracy in correctly identifying CDI.
Treatment delays could lead to more severe outcomes, longer
illness duration and more secondary cases [6], all of which have
implications for bed management and patient outcomes. On the
other hand, the overdiagnosis of CDI could lead to unnecessary
treatment of many patients. Not only can this delay the
appropriate treatment for a patient’s true condition, but also itInfectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 77.e1–77.e9
77.e8 Clinical Microbiology and Infection, Volume 21 Number 1, January 2015 CMIcould contribute to adverse reactions and antibiotic resistance
related to unnecessary antibiotic use. Overdiagnosis will also
falsely elevate C. difﬁcile prevalence rates.
We used toxigenic culture as the reference standard for
diagnostic test sensitivity and speciﬁcity, which is recommended
by the treatment guidelines [2]. Although the true reference
standard may be debated or tarnished, toxigenic culture is
useful for the validation of assay methods [18]. Sensitivity and
speciﬁcity values also will differ with regard to analytic validity
and clinical validity. The studies we used evaluated the diag-
nostic tests for analytic validity or ability of the test to accu-
rately and reliably measure the properties it is intended to
measure [19]); in our case, to detect C. difﬁcile in stool. A
limitation is that relatively few studies evaluate the accuracy of
these diagnostics in diagnosing CDI clinically using symptoms
and diagnostic testing [16].
It is important to note that none of the available diagnostic
tests can make the distinction between asymptomatic coloni-
zation and active infection. This distinction can be determined
only by clinical assessment of a new or changed increase in
stool output that responds to CDI treatment, because the
presence of toxin vs. the toxin gene does not determine active
infection (clinical vs. analytic validity). Therefore, testing of
stools should occur only for those patients experiencing
symptoms consistent with CDI [5]. Guidelines do not recom-
mend treatment or testing for asymptomatic colonization.
Therefore, caution must be taken when utilizing any test in
patients with a low likelihood of CDI (i.e. low pretest
probability).
Diagnostic approaches can affect the CDI incidence rate that
hospitals report [20–22]. Due to the differences in approaches
and other limitations of healthcare-associated infection sur-
veillance, care must be taken with interfacility comparisons of
CDI rates [23]. However, the National Healthcare Safety
Network now calculates standardized infection ratios that
adjust for signiﬁcant risk factors, which include type of test
utilized (i.e. NAAT, EIA, or other) [24]. Additionally, the lack of
consistent diagnostic practices can make it difﬁcult to estimate
the true number of cases that occur [5].
Our model was built to remain conservative about the
beneﬁts garnered from accurate CDI diagnosis. We only
included costs associated with the duration of hospitalization,
yet additional costs may be associated with a longer time frame.
We excluded rare outcomes and patients with comorbid
conditions (e.g. irritable bowel syndrome), which may lead to
additional costs. Turnaround time may vary from facility to
facility, depending on batching and the number of times tests
are run per day. We intended to be conservative by assuming a
1-day turnaround time for all tests to account for hour-to-hour
variation. Additionally, we did not include the potential costs ofClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectthe secondary infections, which can cost a hospital a median
$6000 to $7000 per infection (depending on number of re-
currences) [9], as the primary goal of a diagnostic test or
approach is to impact the care of the patient receiving that test.
Including this cost would have biased our results against a less
speciﬁc and more sensitive diagnostic approach. We assumed
that false-negative cases were as infectious as true-positive
cases; in reality, their transmission may be lower, but there
are a lack of data to quantify this value. Moreover although
patients hospitalized in double occupancy rooms may incur
more costs as they transfer in and out of private rooms based
on their need for isolation precautions, these transfer costs
were not included in our model. Room size also would impact
transmission. However, this issue may become obsolete in the
near future as hospitals renovate their units or build new units
to support single-occupancy rooms. Importantly, all models, by
deﬁnition, are simpliﬁcations of real life [25] and cannot
represent every possible event or outcome.
Lastly, our results are limited by the paucity of studies
examining the test characteristics of C. difﬁcile assays using
clinical infection as a reference standard. Without such data, we
have had to use test characteristics estimated using toxigenic
culture as a reference standard, which does not distinguish
active clinical infection from asymptomatic colonization. This is
relevant because in the real-world setting simulated in our
model, not all patients tested for C. difﬁcile will have a high
probability of having CDI. In those patients, a positive C. difﬁcile
test may be more likely to be a false-positive test than a true-
positive test. This may bias our results in favour of the
NAAT test (which because of its high sensitivity might be ex-
pected to identify more asymptomatic colonisations) and
against the toxin AB EIA test (which is likely more speciﬁc for
clinical infection). Patients at the highest risk of false-positive
results may be those without diarrhoea who are pan-cultured
in the context of a fever in the inpatient setting, or those
with diarrhoea due to another clear source such as laxatives.
Ideally, hospital laboratories should not accept normal formed
stool for testing, which would eliminate the probability of our
ﬁrst hypothetical scenario, but this is not always the case. To
estimate the impact of this potential bias on our ﬁndings, we
performed sensitivity analyses in which we assumed that all
patients entering the model had clinically signiﬁcant diarrhoea
(thus eliminating the possibility of our ﬁrst hypothetical sce-
nario) using test characteristics based on clinical reference
standards for the diagnostics where this data is available, as well
as varying the sensitivity and speciﬁcity of all tests in several
two-way analyses. Our ﬁndings were robust to these analyses.
Future studies should evaluate the sensitivity and speciﬁcity of
all C. difﬁcile diagnostic tests using clinical infection as a refer-
ence standard.ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 77.e1–77.e9
CMI Bartsch et al. Economics of C. difﬁcile diagnostics 77.e9ConclusionsFor patients with clinically signiﬁcant diarrhoea, use of the GDH/
toxin AB combination test with NAAT conﬁrmation of inde-
terminate results was the least costly strategy for the diagnosis of
C. difﬁcile while accurately identifying cases, regardless of the
extent of treatment delays associated with false-negative tests.
Due to its increased sensitivity, diagnosis with this approach leads
to the greatest number of timely treatments with the fewest
treatment delays and unnecessary treatments.Transparency DeclarationFunding: No funding was received for this work.
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